FX006 32 mg
Sponsors
Pacira Pharmaceuticals, Inc
Conditions
Bilateral Knee OsteoarthritisOsteoarthritis of the HipOsteoarthritis of the KneeOsteoarthritis of the ShoulderOsteoarthritis, HipOsteoarthritis, KneePost-traumatic Osteoarthritis of the KneeType 2 Diabetes Mellitus
Phase 2
Study of FX006 vs Normal Saline in Patients With Osteoarthritis of the Knee
CompletedNCT02116972
Start: 2014-04-30End: 2015-11-30Updated: 2024-01-24
Proof of Concept Study Comparing FX006 to Kenalog®-40 in Patients With Post-Traumatic Osteoarthritis of the Knee
TerminatedNCT02468583
Start: 2015-02-28End: 2016-07-31Updated: 2024-01-24
Study to Characterize the PK and Local Extent and Duration of Exposure From FX006 in Patients With OA of the Knee
CompletedNCT02637323
Start: 2015-11-30End: 2016-09-30Updated: 2024-01-24
Study to Assess the Effects of FX006 on Blood Glucose in Patients With OA of the Knee and Type 2 Diabetes
CompletedNCT02762370
Start: 2016-04-30End: 2016-11-30Updated: 2024-01-24
Study to Compare Exposure of TA Following Administration of Either FX006 or TAcs in Patients With Bilateral Knee OA
CompletedNCT03378076
Start: 2017-12-06End: 2018-03-14Updated: 2024-01-24
Study to Compare Exposure of TA Following Administration of FX006 or TAcs in Patients With OA of the Shoulder or Hip
CompletedNCT03382262
Start: 2017-12-18End: 2018-10-09Updated: 2024-01-24
Study to Evaluate a Procedure for Intra-articular Injection of FX006 in Patients With Osteoarthritis of the Hip
CompletedNCT04065074
Start: 2019-07-30End: 2019-12-30Updated: 2024-01-24
Phase 3
Study to Assess the Safety of Repeat Administration of FX006 Administered to Patients With Osteoarthritis of the Knee
CompletedNCT03046446
Start: 2017-02-20End: 2018-07-19Updated: 2024-01-24
Study to Evaluate the Effect of FX006 on Synovial Inflammation in Patients With OA of the Knee
CompletedNCT03529942
Start: 2018-04-24End: 2020-03-09Updated: 2024-01-24